A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
Starting soon · Phase 3 · Has a placebo group
Conditions studied: Overweight, Obesity
In brief
The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development that doctors cannot prescribe yet, but it has been tested in humans before. Participants will be in this clinical study for about 9 months.
Key facts
- Study ID
- NCT07745504
- Run by
- Novo Nordisk A/S
- People needed
- 285
- Starts
- 2026-08-04
- Expected to finish
- 2027-07-06
- Last updated by the study team
- 2026-08-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- Male or female (sex assigned at birth, inclusive of all gender identities).
- Age 18 years or above at the time of signing the informed consent.
- Body mass index (BMI) greater than or equal to (>=) 30.0 kilograms per square meter (kg/m\^2), or BMI >= 27.0 kg/m\^2 with the presence of at least one weight related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
You may not qualify if…
- History of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).
- Previous dosing of marketed or non-marketed amylin-based compounds.
- Treatment, or intention to initiate treatment, with any medication prescribed for the indication of weight management within 180 days before screening.
Where it is running
- Hope Clin Res & Wellness — Conyers, Georgia, United States
- East West Med Res Inst — Honolulu, Hawaii, United States
- Walgreens - Store 11760 — Oak Park, Illinois, United States
- Midwest Inst For Clin Res — Indianapolis, Indiana, United States
- The Alliance for Multispecialty Research LLC AMR — Lexington, Kentucky, United States
- PharmQuest — Greensboro, North Carolina, United States
- KDCILM, LLC & Accellacare US, Inc. — Wilmington, North Carolina, United States
- Coastal Carolina Res Ctr — North Charleston, South Carolina, United States
- Health Res of Hampton Roads — Newport News, Virginia, United States
- National Clin Res Inc. — Richmond, Virginia, United States
- Selma Medical Associates — Winchester, Virginia, United States
- General Hospital Of Athens Alexandra - Department of Endocrinology, Diabetes Center — Athens, Greece
- General Hospital Of Athens G Gennimatas - Department of Endocrinology — Athens, Greece
- General Hospital Venizeleio-Pananeio - Diabetic Clinic — Irakleio, Greece
- Athens Medical Center S.A. (Iatriko Peristeriou) - Diabetes, obesity and cardiometabolic diseases department — Peristeri, Greece
- Ippokratio General Hospital Of Thessaloniki - B' Internal Medicine clinic — Thessaloniki, Greece
- St. Luke's Hospital S.A. - Endocrinology Department and Obesity Clinic — Thessaloniki, Greece
- Stúdium Egészségház Kft. — Kalocsa, Bács-Kiskun county, Hungary
- Borbánya Praxis E.Ü. Kft. — Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungary
- Trial Pharma Kft. — Kecskemét, Hungary
- KomplexLabor Diagnosztika Kft. — Szeged, Hungary
- ULS Do Oeste E.P.E. - Unidade Caldas da Rainha_CAMI - Unidade de Diabetes — Caldas da Rainha, Portugal
- ULS Do Baixo Mondego, E.P.E. - HDFF_Serviço Cirurgia (Esp. Endocrinologia) — Figueira da Foz Municipality, Portugal
- Hospital São Francisco, S.A_EECC — Leiria, Portugal
- APDP - Associação Protectora dos Diabéticos de Portugal — Lisbon, Portugal
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.